Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Motoko Nagata

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Bioorganic & Medicinal Chemistry|November 6, 2009
Discovery of novel thieno[2,3-d]pyrimidin-4-yl hydrazone-based inhibitors of cyclin D1-CDK4: synthesis, biological evaluation and structure-activity relationships. Part 2Takao Horiuchi, Motoko Nagata, Mayumi Kitagawa, et al.
Journal of Biochemistry|July 14, 2010
Identification of a phosphorylation site in c-Ski as serine 515Motoko Nagata, Shinji Nagata, Keiko Yuki, et al.
Chemical & Pharmaceutical Bulletin|August 2, 2011
Discovery of novel Thieno[2,3-d]pyrimidin-4-yl hydrazone-based cyclin-dependent kinase 4 inhibitors: synthesis, biological evaluation and structure-activity relationshipsTakao Horiuchi, Yasuyuki Takeda, Noriyasu Haginoya, et al.
Genes to Cells : Devoted to Molecular & Cellular Mechanisms|March 14, 2007
c-Ski activates MyoD in the nucleus of myoblastic cells through suppression of histone deacetylasesNorihiko Kobayashi, Kouichiro Goto, Kana Horiguchi, et al.
Genes to Cells : Devoted to Molecular & Cellular Mechanisms|October 24, 2006
Nuclear and cytoplasmic c-Ski differently modulate cellular functionsMotoko Nagata, Kouichiro Goto, Shogo Ehata, et al.
Bioorganic & Medicinal Chemistry Letters|May 20, 2004
New highly active taxoids from 9 beta-dihydrobaccatin-9,10-acetals. Part 5Yasuyuki Takeda, Kouichi Uoto, Michio Iwahana, et al.
International Journal of Clinical Oncology|February 12, 2025
Human epidermal growth factor receptor 3 expression in patients with epithelial ovarian cancer: a potential target for ovarian mucinous and clear cell carcinomaSho Sato, Daisuke Shintani, Yuki Kaneda, et al.
Molecular Cancer Therapeutics|January 11, 2024
Raludotatug Deruxtecan, a CDH6-Targeting Antibody-Drug Conjugate with a DNA Topoisomerase I Inhibitor DXd, Is Efficacious in Human Ovarian and Kidney Cancer ModelsHirokazu Suzuki, Shotaro Nagase, Chiemi Saito, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Bioorganic & Medicinal Chemistry|November 6, 2009
Discovery of novel thieno[2,3-d]pyrimidin-4-yl hydrazone-based inhibitors of cyclin D1-CDK4: synthesis, biological evaluation and structure-activity relationships. Part 2Takao Horiuchi, Motoko Nagata, Mayumi Kitagawa, et al.
Journal of Biochemistry|July 14, 2010
Identification of a phosphorylation site in c-Ski as serine 515Motoko Nagata, Shinji Nagata, Keiko Yuki, et al.
Chemical & Pharmaceutical Bulletin|August 2, 2011
Discovery of novel Thieno[2,3-d]pyrimidin-4-yl hydrazone-based cyclin-dependent kinase 4 inhibitors: synthesis, biological evaluation and structure-activity relationshipsTakao Horiuchi, Yasuyuki Takeda, Noriyasu Haginoya, et al.
Genes to Cells : Devoted to Molecular & Cellular Mechanisms|March 14, 2007
c-Ski activates MyoD in the nucleus of myoblastic cells through suppression of histone deacetylasesNorihiko Kobayashi, Kouichiro Goto, Kana Horiguchi, et al.
Genes to Cells : Devoted to Molecular & Cellular Mechanisms|October 24, 2006
Nuclear and cytoplasmic c-Ski differently modulate cellular functionsMotoko Nagata, Kouichiro Goto, Shogo Ehata, et al.
Bioorganic & Medicinal Chemistry Letters|May 20, 2004
New highly active taxoids from 9 beta-dihydrobaccatin-9,10-acetals. Part 5Yasuyuki Takeda, Kouichi Uoto, Michio Iwahana, et al.
International Journal of Clinical Oncology|February 12, 2025
Human epidermal growth factor receptor 3 expression in patients with epithelial ovarian cancer: a potential target for ovarian mucinous and clear cell carcinomaSho Sato, Daisuke Shintani, Yuki Kaneda, et al.
Molecular Cancer Therapeutics|January 11, 2024
Raludotatug Deruxtecan, a CDH6-Targeting Antibody-Drug Conjugate with a DNA Topoisomerase I Inhibitor DXd, Is Efficacious in Human Ovarian and Kidney Cancer ModelsHirokazu Suzuki, Shotaro Nagase, Chiemi Saito, et al.
Pageof 1